RxDoctor Payments Data

Sudhathi Chennuru, MD

Hematology & Oncology · Kettering, OHNPI 1689740326

Payments from drug & device makers

$15,608in general payments, 2019–2025

Across 48 payments — averaging $325.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$15K
  • Novartis$128
  • Sanofi$112
  • Merck$111
  • Exelixis Inc.$80
  • Gilead$75
  • plus $570 from 17 others

What the payments were for

  • Food & beverage$91885%
  • Education$15815%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$15,608 in reported general payments places this provider in the 60th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$48,346
Medicare patients
161
Services billed
451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TasignaNilotinib Hcl25$443,118
DopteletAvatrombopag Maleate18$282,283
Lenalidomide14$244,509
JakafiRuxolitinib Phosphate14$242,028
LenvimaLenvatinib Mesylate11$238,888
PromactaEltrombopag Olamine15$206,181
ImbruvicaIbrutinib12$196,053
CalquenceAcalabrutinib Maleate13$185,651
XareltoRivaroxaban19$16,494
EliquisApixaban24$13,490
Fentanyl11$1,029
Anastrozole88$1,000
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen26$875
Acyclovir33$701
Hydroxyurea25$521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisTasigna, Promacta$128$649,29940 claims
Eisai Inc.Lenvima$40$238,88811 claims
AstraZenecaCalquence$42$185,65113 claims
Johnson & JohnsonXarelto$47$16,49419 claims
PfizerEliquis$26$13,49024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Kettering

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →